Presentation is loading. Please wait.

Presentation is loading. Please wait.

The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action.

Published byEzra Hensley Modified over 6 years ago

Similar presentations

Presentation on theme: "The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action."— Presentation transcript:

1 The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action (MOA) by which cells are killed. The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action (MOA) by which cells are killed. All indicated linker/triggers and drugs, except amanitin, are under clinical investigation as ADCs. Paul Polakis Pharmacol Rev 2016;68:3-19 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics

Download ppt "The three primary ADC components that determine which cells are targeted (antibody), how the drug is released (linker/trigger), and the mechanism of action."

Similar presentations

Dementia-Pipeline Review, H Phone No.: +1 (214) id:

Dementia-Pipeline Review, H Phone No.: +1 (214) id:
Representative 10-s EEG recordings from GAERS: during baseline (prior to injection of any drug) (i), following the i.c.v. injection of 4 μl of vehicle.

Representative 10-s EEG recordings from GAERS: during baseline (prior to injection of any drug) (i), following the i.c.v. injection of 4 μl of vehicle.
Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.

Antibody Drug Conjugates Services Antibody-drug conjugates Antibody-drug conjugates (ADCs) are a very important class of highly potent drugs designed as.
Production and clinical development of nanoparticles for gene delivery

Production and clinical development of nanoparticles for gene delivery
TNFR1 and TNFR2 are expressed on native human ASM but activation of TNFR1 mediates ICAM-1 expression in human ASM cells. TNFR1 and TNFR2 are expressed.

TNFR1 and TNFR2 are expressed on native human ASM but activation of TNFR1 mediates ICAM-1 expression in human ASM cells. TNFR1 and TNFR2 are expressed.
Cytokine-induced rapid ICAM-1 expression on human ASM promotes adhesion of activated T lymphocytes. Cytokine-induced rapid ICAM-1 expression on human ASM.

Cytokine-induced rapid ICAM-1 expression on human ASM promotes adhesion of activated T lymphocytes. Cytokine-induced rapid ICAM-1 expression on human ASM.
Htr-9 stimulates ICAM-1 gene expression in human ASM cells.

Htr-9 stimulates ICAM-1 gene expression in human ASM cells.
Darts Sciences https://www.dartssciences.com. Darts Target Identification.

Darts Sciences Darts Target Identification.
Mc-vc-pab-mmae This ADC product is composed of an anti-TENB2 antibody (clone anti- TENB2) conjuagated via a MC-VC-PABC linker to MMAE (Thio-anti- TENB2-MC-vc-PAB-MMAE).

Mc-vc-pab-mmae This ADC product is composed of an anti-TENB2 antibody (clone anti- TENB2) conjuagated via a MC-VC-PABC linker to MMAE (Thio-anti- TENB2-MC-vc-PAB-MMAE).
Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.
Parallels in antimicrobial peptide mechanisms of action and resistance

Parallels in antimicrobial peptide mechanisms of action and resistance
Requirement for a β subunit for the modulation of whole-cell CaV2

Requirement for a β subunit for the modulation of whole-cell CaV2
Genome-editing Technologies for Gene and Cell Therapy

Genome-editing Technologies for Gene and Cell Therapy
Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.

Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.
Evaluation of models incorporating the base covariates.

Evaluation of models incorporating the base covariates.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
The context-sensitive half-times for commonly used intravenous anesthetic drugs. [Reproduced from Reves JG, Glass PSA, Lubarsky DA, McEvoy MD, and Martinez-Ruiz.

The context-sensitive half-times for commonly used intravenous anesthetic drugs. [Reproduced from Reves JG, Glass PSA, Lubarsky DA, McEvoy MD, and Martinez-Ruiz.
Figure 2 Circadian and ultradian fluctuations in corticosterone

Figure 2 Circadian and ultradian fluctuations in corticosterone
A, reversed phase HPLC separation and profile of products from HUVEC and human PMN coincubations. A, reversed phase HPLC separation and profile of products.

A, reversed phase HPLC separation and profile of products from HUVEC and human PMN coincubations. A, reversed phase HPLC separation and profile of products.
Retroviral vector propagation in helper cells and structure of a prototypical vector. Retroviral vector propagation in helper cells and structure of a.

Retroviral vector propagation in helper cells and structure of a prototypical vector. Retroviral vector propagation in helper cells and structure of a.

Similar presentations

Ads by Google